Status:
COMPLETED
Effects of Adrenal Artery Ablation and Adrenalectomy in Patients With Primary Aldosteronism
Lead Sponsor:
Third Military Medical University
Conditions:
Primary Aldosteronism
Hypertension
Eligibility:
All Genders
30-65 years
Brief Summary
Primary aldosteronism (PA) is the main cause of secondary hypertension, affecting 5-15% of the general hypertensive population. Early diagnosis and treatment are of crucial importance as patients with...
Eligibility Criteria
Inclusion
- Primary aldosteronis diagnosed by increased aldosterone-to-renin ratio (ARR) and serum aldosterone levels ≥15 ng / dl, and confirmed by saline injection test or captopril inhibition test.
- Aldosteronoma had lateralization by adrenal venous sampling (AVS) and confirmed with CT
- Signed informed consent and agreed to participate in this study.
Exclusion
- Aldosterone cancer.
- Hyperkalemia.
- Renal failure or the following history of nephropathy: serum creatinine 1.5 times higher than the upper limit; dialysis history; or nephrotic syndrome.
- Secondary hypertension except the primary aldosteronism.
- Adrenergic insufficiency.
- Heart failure with NYHA Ⅱ-Ⅳ grade or unstable angina, severe cardiovascular and cerebrovascular stenosis, myocardial infarction, intracranial aneurysm, stroke and other acute cardiovascular events.
- Acute infections, tumors and severe arrhythmias, psychiatric disorders, drugs or alcohol addicts.
- Liver dysfunction or the following history of liver disease: AST or ALT 2 times higher than the upper limit, liver cirrhosis, history of hepatic encephalopathy, esophageal variceal history or portal shunt history.
- Coagulation dysfunction.
- Pregnant women or lactating women.
- Participated in other clinical trials or admitted with other research drugs within 3 months prior to the trial.
- Allergy or any contraindications for contrast agents and alcohol.
- Refused to sign informed consent
Key Trial Info
Start Date :
January 19 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2021
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT04269928
Start Date
January 19 2016
End Date
June 1 2021
Last Update
March 22 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The third hospital affiliated to the Army Medical University
Chongqing, Chongqing Municipality, China, 400042